Despite evidence that pathological Aβ and tau can induce synapse dysfunction in model systems1,3–5 and reports that novel Aβ-targeting antibodies can, modestly, slow cognitive decline6–8, AD research has had limited translational success1,9,10. This evidence concerns the gene MAPT and Alzheimer disease.